

Oxcarbazepine (Trileptal®, Oxtellar XR®)

Selected References:

- Amaral De Lara IC, et al. 2025. Association of prenatal exposure to antiseizure medication with risk of autism: a systematic review and meta-analysis. *Seizure*; 130:41-47.
- Adrade C. 2024. Epilepsy, antiepileptic drugs, and adverse pregnancy outcomes, 2: Major congenital malformations with antiepileptic drug monotherapy. *J Clin Psychiatry*; 85(3):24f15432.
- Artama M, et al. 2006. Antiepileptic drug use and birth rate in patients with epilepsy-a population-based cohort study in Finland. *Hum Reprod*; 21:2290-2295.
- Battino D, et al. 2024. Risk of major congenital malformations and exposure to antiseizure medication monotherapy. *JAMA Neurol*; 82(5):481-489.
- Bech LF, et al. 2018. In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. *J Neurol Neurosurg Psychiatry*; 89:1324-1331.
- Birnbaum AK, et al. 2020. Antiepileptic drug exposure in infants of breastfeeding mothers with epilepsy. *JAMA Neurol*; 77(4):441-450.
- Bjork M-H, et al. 2022. Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability. *JAMA Neurology*; 79(7):672-681.
- Blotière PO, et al. 2019. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. *Neurology*; 93(2):e167-e80.
- Blotière PO, et al. 2020. Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. *BMJ Open*; 10(6):e034829.
- Bruno MK, Harden CL. 2002. Epilepsy in pregnant women. *Curr Treat Options Neurol*; 4(1):31-40.
- Büllau P, et al. 1988. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. *Eur J Clin Pharmacol*; 34:311-313.
- Chen CY, et al. 2017. In utero oxcarbazepine exposure and neonatal abstinence syndrome: Case report and brief review of the literature. *Pharmacotherapy*; 37:e71-e5.
- Christensen J, et al. 2015. Apgar-score in children prenatally exposed to antiepileptic drugs: a population-based cohort study. *BMJ Open*; 5(9):e007425.
- Cohen JM, et al. 2019. Anticonvulsant mood stabilizer and lithium use and risk of adverse pregnancy outcomes. *J Clin Psychiatry*; 80(4).
- Cohen JM, et al. 2023. Comparative safety of antiseizure medication monotherapy for major malformations. *Ann Neurol*; 93(3):551-562.
- Daugaard CA, et al. 2020. Association of prenatal exposure to valproate and other antiepileptic drugs with intellectual disability and delayed childhood milestones. *JAMA Netw Open*; 3(11):e2025570.
- Dreier JW et al. 2023. Prenatal exposure to antiseizure medication and incidence of childhood- and adolescence-onset psychiatric disorders. *JAMA Neurology*; 80(6):568-577.
- Eisenschenk S. 2006. Treatment with oxcarbazepine during pregnancy. *Neurologist*; 12(5):249-254.
- Friis ML, et al. 1993. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. *Acta Neurol Scand*; 87(3):224-227.
- Gentile S. 2003. Oxcarbazepine in pregnancy and lactation. *Clin Drug Investig*; 23:687.
- Guo Y, et al. 2021. A comparative study of the effects of valproate and oxcarbazepine on sexual function, sperm quality, and sex hormones in males with epilepsy. *Biomed Res Int*; 2021:6624101.
- Hvas CL, et al. 2000. Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birthweight. *Br J Obstet Gynaecol*; 107:896-902.
- Hernandez-Diaz S, et al. 2025. Use of antiseizure medications early in pregnancy and the risk of major

malformations in the newborn. *Neurology*; 105(3):e213786.

- Honybun E, et al. Neurodevelopmental and functional outcomes following in utero exposure to antiseizure medication: a systematic review. *Neurology*; 102(8):e209175.
- Isojarvi JJ, et al. 2004. Effect of epilepsy and antiepileptic drugs on male reproductive health. *Neurology*; 62:247-253.
- Jacobsen PE, et al. 2014. Prenatal exposure to antiepileptic drugs and dental agenesis. *PLoS One*; 9(1):e84420.
- Johnson K, et al. 2021. Retrospective Analysis of Oxcarbazepine in Pregnant Women With Substance Use Disorders: Focus on Safety. *Journal of Pharmacy Practice*; 34(1):28-34.
- Kaaja E, et al. 2003. Major malformations in offspring of women with epilepsy. *Neurology*; 60:575-579.
- Kim HK, et al. 2026. Prenatal Exposure to Antiseizure Medications and the Risk of Congenital Anomalies: A Nationwide Population-Based Study in South Korea. *Neurology*; 106(1):e214350.
- Lloyd P, et al. 1994. Clinical Pharmacology and Pharmacokinetics of Oxcarbazepine. *Epilepsia*; 35(s3).
- Luef G, et al. 2009. Oxcarbazepine treatment in male epilepsy patients improves pre-existing sexual dysfunction. *Neurologica*; 119(2):94-99.
- Lutz UC, et al. 2007. Oxcarbazepine treatment during breast-feeding: a case report. *J Clin Psychopharmacol*; 27:730-732.
- Meischenguiser R, et al. 2003. Major malformations in offspring of women with epilepsy. [Letter] *Neurology*; 61:1631.
- Meischenguiser R, et al. 2004. Oxcarbazepine in pregnancy: clinical experience in Argentina. *Epilepsy Behav*; 5:163-167.
- Miller M, et al. 2003. Major malformations in offspring of women with epilepsy. [Letter] *Neurology*; 61:1631.
- Mølgaard-Nielsen D, Hviid A. 2011. Newer-generation antiepileptic drugs and the risk of major birth defects. *JAMA*; 305(19):1996-2002.
- Montouris G. 2005. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. *Curr Med Res Opin*; 21:693-701.
- Novartis. 2020. Trileptal® Prescribing Information. Available at URL: <https://www.novartis.us/sites/www.novartis.us/files/trileptal.pdf>.
- Ohman I, et al. 2009. Pharmacokinetics of oxcarbazepine in neonatal period and during lactation. *Epilepsia*; 50(Suppl. 4):238. Abstract.
- Rolnitsky A, et al. 2013. In utero oxcarbazepine and a withdrawal syndrome, anomalies, and hyponatremia. *Pediatr Neurol*; 2013;48(6):466-468.
- Supernus Pharmaceuticals. 2018. Oxtellar XR® Prescribing Information. Available at URL: <https://www.oxtellarxrhcp.com/assets/OxtellarXRPrescribingInformation.pdf>.
- Straub L, et al. 2026. Prenatal antiseizure drug exposure and risk of neurodevelopmental disorders in children: population based cohort study. *BMJ*; 392:e085725.
- The Centers for Disease Control and Prevention (CDC). 2025. Folic Acid: Sources and Recommended Intake. Available at <https://www.cdc.gov/folic-acid/about/intake-and-sources.html> [Accessed 03/2026].
- Tomson T, et al. 2015. Antiepileptic drugs and intrauterine death: A prospective observational study from EURAP. *Neurology*; 85: 580-588.
- Tomson T, et al. 2018. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. *Lancet Neurol*; 17(6):530-538.
- Trivedi M, et al. 2018. Spontaneous fetal loss in women with epilepsy: prospective data from pregnancy registry in India. *Epilepsy Research*; 146:50-53.
- Vajda F, et al. 2018. Anti-epileptic drug exposure and risk of foetal death in utero. *Acta Neurol Scand*; 137(1):20-23.
- Veiby G, et al. 2014. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. *J Neurol*; 261:579-588.
- Videman M, et al. 2016. Evidence for spared attention to faces in 7-month-old infants after prenatal exposure to

antiepileptic drugs. *Epilepsy Behav*; 64(Pt A):62-68.

- Weston J, et al. 2016. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. *Cochrane Database Syst Rev*; 11(11):CD010224.
- Wu D, et al. 2018. The effects of oxcarbazepine, levetiracetam, and lamotrigine on semen quality, sexual function, and sex hormones in male adults with epilepsy. *Epilepsia*; 59(7):1344-1350.
- Yin X, et al. 2022. Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy. *CNS Neurosci Ther*; 28(5):658-666.

Mga Tanong? Tumawag sa 866.626.6847 | Mag-text sa 855.999.3525 | Mag-email o Makipag-chat sa [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, March 1, 2026.

Oxcarbazepine (Trileptal®, Oxtellar XR®)

Selected References:

- Gallagher M. 2018. Exposure to Dihydroxyacetone in Sunless Tanning Products. Understanding the Risks. *J Dermatol Nurses Assoc*. 10(1):11-17.
- Meadows M. 2003. Don't be in the dark about tanning. *FDA Consumer Magazine*, 37:6.
- Turner J et al. 2023. In search of the perfect tan: Chemical activity, biological effects, business considerations, and consumer implications of dihydroxyacetone sunless tanning products. *J Cosmet Dermatol*. 22(1):79-88.
- United States Food and Drug Administration (FDA). 2022. Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Available at <https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra>.
- United States Food and Drug Administration (FDA). 2024. Sunless tanners and bronzers. Available at <https://www.fda.gov/cosmetics/cosmetic-products/sunless-tanners-bronzers>
- Yourick JJ, et al. 2004. Fate of chemicals in skin after dermal application: Does the in vitro skin reservoir affect the estimate of systemic absorption? *Toxicol Appl Pharmacol*, 195:309-320.

Mga Tanong? Tumawag sa 866.626.6847 | Mag-text sa 855.999.3525 | Mag-email o Makipag-chat sa MotherToBaby.org.

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, March 1, 2026.

Oxcarbazepine (Trileptal®, Oxtellar XR®)

Selected References

- Ankarfeldt MZ, et al. 2021. Exposure to duloxetine during pregnancy and risk of congenital malformations and stillbirth: A nationwide cohort study in Denmark and Sweden. *PLOS Medicine*, 18(11):e1003851.
- Ankarfeldt MZ, et al. 2023. Duloxetine exposure during pregnancy and the risk of offspring being born small for gestational age or prematurely: A nationwide Danish and Sweden safety study. *Drugs Real World Outcomes*, 10(1):69-81.
- Bellantuono C, et al. 2015. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. *Hum Psychopharmacol*, 30(3):143-51.
- Gentile S, et al. 2019. Managing fibromyalgia syndrome in pregnancy no bridges between USA and EU. *Archives of Women's Mental Health*, 22(6):711-721.
- Hoog SL, et al. 2013. Duloxetine and pregnancy outcomes: safety surveillance findings. *International Journal of Medical Sciences*. 10(4):413-419.
- Huybrechts KF, et al. 2020 Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. *BMJ* 368:m237.
- Kallen B, et al. 2013. The use of central nervous system active drugs during pregnancy. *Pharmaceuticals*. 6(10):1221-1286.
- Kjaersgaard MI, et al. 2013. Prenatal antidepressant exposure and risk of spontaneous abortion – a population-based study. *PLoS One*, 8(8):e72095.
- Lassen D, et al. 2016. First-Trimester Pregnancy Exposure to Venlafaxine or Duloxetine and Risk of Major Congenital Malformations: A Systematic Review. *Basic & clinical pharmacology & toxicology*. 118(1):32-6. doi:10.1111/bcpt.12497.
- Liu D, et al. 2025. Uncovering safety signals of duloxetine: Real-world evidence from the FAERS database. *J Affect Disord*. 388:119517. doi:10.1016/j.jad.2025.119517
- Marks C, et al. 2021. Comparing newborn outcomes after prenatal exposure to individual antidepressants: a retrospective cohort study. *Pharmacotherapy* 41(11):907-914.
- Punjani N, et al. 2021. Impact of duloxetine on male fertility: A randomized controlled clinical trial. *Andrologia*, 53(10):e14207.
- Richendrfer H, et al. 2018. Cluster analysis profiling of behaviors in zebrafish larvae treated with

antidepressants and pesticides. *Neurotoxicology Teratology*, 69:54-62.

Mga Tanong? Tumawag sa 866.626.6847 | Mag-text sa 855.999.3525 | Mag-email o Makipag-chat sa [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, March 1, 2026.

Oxcarbazepine (Trileptal®, Oxtellar XR®)

Selected References:

- Aarskog D. 1975. Association between maternal intake of diazepam and oral clefts. *Lancet*. 2:921.
- Borgatta L, et al. 1997. Clinical significance of methohexital, meperidine, and diazepam in breast milk. *J Clin Pharmacol*. 37:186-92.
- Brandlistuen R, et al. 2017. Association of prenatal exposure to benzodiazepines and child internalizing problems: A sibling-controlled cohort study. *PLoS One*. 12(7):e0181042.
- Calderon-Margalit R, et al. 2009. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. *Am J Obstet Gynecol*. 201(6):579.e1-579.e1-8.
- Chen VC, et al. 2022. Association of prenatal exposure to benzodiazepines with development of autism spectrum and attention-deficit/hyperactivity disorders. *JAMA Netw Open*. 5(11): e2243282.
- Czeizel A. 1987. Lack of evidence of teratogenicity of benzodiazepine drugs in Hungary. *Reprod Toxicol*. 1(3):183-188.
- Czeizel A, et al. 1999. The effect of diazepam and promethazine treatment during pregnancy on the somatic development of human offspring. *Neurotoxicol Teratol*. 21(2):157-167.
- Diazepam drug label. 2025.
<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=167ee280-be68-4a28-a7d8-de41df14bc48&audience=consumer>
- Engeland A, et al. 2013. Effects of preconceptional paternal drug exposure on birth outcomes: cohort study of 340 000 pregnancies using Norwegian population-based databases. *Br J Clin Pharmacol*. 75(4):1134-1141.
- Freeman MP, et al. 2018. Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: Results from a prospective registry of women with psychiatric disorders. *Gen Hosp Psychiatry* 53:73-79.

- Gilder ME, et al. 2021. Outcomes for 298 breastfed neonates whose mothers received ketamine and diazepam for postpartum tubal ligation in a resource-limited setting. *BMC Pregnancy Childbirth*. 21(1):121.
- Grigoriadis S, et al. 2020. Pregnancy and delivery outcomes following benzodiazepine exposure: a systematic review and meta-analysis. *Can J Psychiatry*. 65(12): 821-834.
- Iqbal MM, et al. 2002. Diazepam use during pregnancy: a review of the literature. *Del Med J*. 74(3):127-135.
- Jensen AG, et al. 2022. Prenatal exposure to benzodiazepines and the development of the offspring: a systematic review. *Neurotoxicol Teratol*. 91:107078.
- Jørgensen NP, et al. 1988. Pharmacokinetics and distribution of diazepam and oxazepam in early pregnancy. *Acta Obstet Gynecol Scand*. 67(6):493-497.
- Kjaer D, et al. 2007. Use of phenytoin, phenobarbital, or diazepam during pregnancy and risk of congenital abnormalities: a case-time-control study. *Pharmacoepidemiol Drug Saf*. 16(2):181-188.
- Laegreid L, et al. 1990. Congenital malformations and maternal consumption of benzodiazepines: a case-control study. *Dev Med Child Neurol*. 32(5):432-441.
- Laegreid L, et al. 1992. Neurodevelopment in late infancy after prenatal exposure to benzodiazepines—a prospective study. *Neuropediatrics*. 23(2):60-67.
- L, et al. 1992. The effect of benzodiazepines on the fetus and the newborn. *Neuropediatrics*. 23(1):18-23.
- Noh Y, et al. 2022. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: A population-based cohort study in South Korea. *PLoS Med*. 19(3): e1003945.
- Ornoy A, et al. 1998. Is benzodiazepine use during pregnancy really teratogenic? *Reprod Toxicol*. 12(5):511-515.
- Rementeria J, Bhatt K. 1977. Withdrawal symptoms in neonates from intrauterine exposure to diazepam. *J Pediatr*. 90(1):123-126.
- Rosenberg L, et al. 1983. Lack of relation of oral clefts to diazepam use during pregnancy. *N Engl J Med*. 309(21):1282-1285.
- Safra M, Oakley GP. 1975. Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. *Lancet*. 2(7933):478-480.
- Salisbury AL, et al. 2016. The Roles of Maternal Depression, Serotonin Reuptake Inhibitor Treatment, and Concomitant Benzodiazepine Use on Infant Neurobehavioral Functioning Over the First Postnatal Month. *Am J Psychiatry*. 173(2):147-157.
- Saxen I, Saxen L. 1975. Association between maternal intake of diazepam and oral clefts. *Lancet*. 2(7933):498.
- Shiono PH, Mills JL. 1984. Oral clefts and diazepam use during pregnancy. *N Engl J Med*. 311(14):919-920.
- Sundbakk LM, et al. 2022. Association of prenatal exposure to benzodiazepines and Z-hypnotics with risk of attention-deficit/hyperactivity disorder in childhood. *JAMA Netw Open*. 5(12): e2246889.
- Szpunar MJ, et al. 2022. Risk of major malformations in infants after first-trimester exposure to benzodiazepines: Results from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. *Depress Anxiety*. 39(12):751-759.
- Uguz F. 2021. A new safety scoring system for the use of psychotropic drugs during lactation. *Am J Ther*. 2021;28:e118-e126.
- Valium Drug label. 2025.
<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=554baee5-b171-4452-a50a-41a0946f956c&audience=consumer>
- Wall-Wieler E, et al. 2020. Benzodiazepine use before conception and risk of ectopic pregnancy. *Hum Reprod*. 35(7):1685-1692.
- Wang X, et al. 2022. Prenatal exposure to benzodiazepines and Z-drugs in humans and risk of adverse neurodevelopmental outcomes in offspring: A systematic review. *Neurosci Biobehav Rev*. 137:10464.
- Wesson DR, et al. 1985. Diazepam and desmethyldiazepam in breast milk. *J Psychoactive Drugs*. 17(1):55-56.
- Wikner BN, et al. 2007. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. *Pharmacoepidemiol Drug Saf*. 16(11):1203-1210.
- Yonkers KA, et al. 2017. Association of panic disorder, generalized anxiety disorder, and benzodiazepine

treatment during pregnancy with risk of adverse birth outcomes. JAMA Psychiatry. 74(11):1145-1152.

Mga Tanong? Tumawag sa 866.626.6847 | Mag-text sa 855.999.3525 | Mag-email o Makipag-chat sa [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, March 1, 2026.

Oxcarbazepine (Trileptal®, Oxtellar XR®)

Selected References:

- Bandoli G, et al. 2010 Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. Br J Dermatol; 163(2):334-339.
- Ben-David G, et al. 2008. Pregnancy outcome in women with psoriasis. J Reprod Med; 53(3):183-187.
- Berman M, et al. 2018. The effect of pregnancy on disease activity in patients with psoriatic arthritis. J Rheumatol; 45(12):1651-1655.
- Bobotsis R, et al. 2016. Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. Br J Dermatol; 175(3):464-472.
- Bröms G, et al. 2018. Effect of maternal psoriasis on pregnancy and birth Outcomes: A population-based cohort study from Denmark and Sweden. Acta Derm Venereol; 98(8):728-734.
- Butler DC, et al. 2014. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol; 70(3):417.e1-10; quiz 427.
- Caldarola G, et al. 2017. Untreated psoriasis impairs male fertility: A case-control study. Dermatology; 233(2-3):170-174.
- Carman WJ, et al. 2017. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf; 26(9):1109-1118.
- Cohen-Barak E, et al. 2011. Pregnancy outcomes in women with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol; 25(9):1041-1047.
- Eudy AM, et al. 2020. Pregnancy outcomes, fertility, and family planning in with psoriatic arthritis. Obstet Med; 13(2):70-75.

- Gladman DD, et al. 2005. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. *Ann Rheum Dis*; 64 Suppl 2:ii14-17.
- Harder E, et al. 2014. No increased risk of fetal death or prolonged time to pregnancy in women with psoriasis. *Invest Dermatol*; 34(6):1747-1749.
- Huerta C, et al. 2007. Incidence and Risk Factors for Psoriasis in the General Population. *Arch Dermatol*; 143(12):1559-1565.
- Johansen CB, et al. 2022. Psoriasis and adverse pregnancy outcomes: A nationwide case-control study in 491,274 women in Denmark. *JAAD; Int* 7: 146-155.
- Kerola AM, et al. 2024. Patterns of reproductive health in inflammatory rheumatic diseases and other immune-mediated diseases: a nationwide registry study. *Rheumatology (Oxford)*. keae122. PMID: 38503536.
- Kimball AE et al. 2021. Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR) *JAMA Dermatol*; 157(3): 1-6.
- Meissner Y, et al. 2021. Pregnancy in women with psoriatic arthritis: A systematic literature review of disease activity and adverse pregnancy outcomes. *Semin Arthritis Rheum*; 51(3):530-538.
- Meserve J, et al. 2021. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients with Immune-Mediated Inflammatory Diseases. *Gastroenterology*; 161(1):107-115.
- Lima XT, et al. 2012. The impact of psoriasis on pregnancy outcomes. *J Invest Dermatol*; 132(1):85-91.
- McMullan P, et al. 2024. Safety of dermatologic medications in pregnancy and lactation: An Update – Part I: Pregnancy. *J Am Acad Dermatol*; S0190-9622(24)00109-9.
- Murase JE, et al. 2005. Hormonal effect on psoriasis in pregnancy & post-partum. *Arch Dermatol*; 141(5):601-606.
- Murase JE, et al. 2014. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. *J Am Acad Dermatol*; 70(3):401.e1-14.
- Ostensen M. 1992. The effect of pregnancy on ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis. *Am J Reprod Immunol*; 28(3-4):235-237.
- Polachek A, et al. 2018. Outcome of pregnancy in women with psoriatic arthritis compared to healthy controls. *Clinic Rheum*; 38: 895-902.
- Rademaker M, et al. 2018. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. *Australas J Dermatol*; 59(2):86-100.
- Rahmati S, et al. 2023. Impact of maternal psoriasis on adverse maternal and neonatal outcomes: a systematic review and meta-analysis. *BMC Pregnancy Childbirth*; 23(1):703.
- Raychaudhuri SP, et al. 2003. Clinical course of psoriasis during pregnancy. *Int J Dermatol*; 42(7):518-20.
- Remaeus K, et al. 2019. Maternal and infant pregnancy outcomes in women with psoriatic arthritis: a Swedish nationwide cohort study. *BJOG*; 126(10):1213-1222.
- Secher AEP, et al. 2025. Preterm birth in women with psoriatic arthritis: what are the risks and risk factors? A collaborative cohort study from Sweden, Denmark and Norway. *RMD Open*; 11(4):e005614.
- Seeger JD, et al. 2007. Pregnancy and pregnancy outcome among women with inflammatory skin diseases. *Dermatol*; 214(1):32-39.
- Smith C, et al. 2020. Birth outcomes and disease activity during pregnancy in a prospective cohort of women with psoriatic arthritis and ankylosing spondylitis. *Amer Col Rheum*; 72(7):1029-1037
- Tuğrul Ayanoğlu B, et al. 2018. Diminished ovarian reserve in patients with psoriasis. *Taiwan J Obstet Gynecol*; 57(2):227-230.
- Ursin K, et al. 2018. Disease activity of psoriatic arthritis during and after pregnancy: A prospective multicenter study. *Arthritis Care Res (Hoboken)*; 71(8):1092-1100.
- Yaghi M, et al. 2024. Safety of Dermatologic Medications in Pregnancy and Lactation: An Update – Part II: Lactation. *J Am Acad Dermatol*; S0190-9622(24)00110-5.
- Yang YW, et al. 2011. Psoriasis and pregnancy outcomes: a nationwide population-based study. *J Am Acad Dermatol*; 64(1):71-77.
- Yiu ZZ, et al. 2014. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in

male and female patients. Br J Dermatol; 171(3):485-491.

- Yiu ZZ, et al. 2015. Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. J Dermatolog Treat; 30:1-6.

Mga Tanong? Tumawag sa 866.626.6847 | Mag-text sa 855.999.3525 | Mag-email o Makipag-chat sa [MotherToBaby.org](https://www.MotherToBaby.org)..

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, March 1, 2026.